Market Overview

Global Cancer Vaccine Partnering Deal Trends, Players, Financials Report 2010-2016 - Research and Markets


Research and Markets has announced the addition of the "Global Cancer Vaccine Partnering 2010-2016: Deal trends, players, financials and forecasts" report to their offering.

The Global Cancer Vaccine Partnering 2010-2016 report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an understanding and analysis of how and why companies enter cancer vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

This report provides details of the latest cancer vaccine agreements announced in the healthcare sectors covering the following diagnostics types including adjuvant:

  • Attenuated vaccine
  • Subunit vaccine
  • Toxoid vaccine
  • Conjugate vaccine
  • Inactivated vaccine
  • DNA vaccine
  • Recombinant vector vaccine

Report scope

  • Trends in cancer vaccine dealmaking in the biopharma industry since 2010
  • Analysis of cancer vaccine deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to over 150 cancer vaccine deal records
  • The leading cancer vaccine deals by value since 2010

In Global Cancer Vaccine Partnering 2010-2015 , the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific oncology therapy target

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Cancer Vaccine dealmaking

Chapter 3 - Leading Cancer Vaccine deals

Chapter 4 - Most active Cancer Vaccine dealmakers

Chapter 5 - Cancer Vaccine contracts dealmaking directory

Chapter 6 - Cancer Vaccine dealmaking by technology type

Chapter 7 - Partnering resource center

For more information about this report visit

Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Cancer Vaccines

View Comments and Join the Discussion!